ABVC Biopharma Inc
ABVC Biopharma Inc is a biotechnology company focused on the development and commercialization of innovative therapies for the treatment of cancer and other serious diseases.
Business. ABVC Biopharma Inc (ABVC.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ABVC Biopharma Inc (ABVC.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
ABVC Biopharma Inc has a market capitalization of $27.48 million and a price-to-book ratio of 3.53, indicating that the market is valuing the company's equity at a premium relative to its book value. The company's liquidity position is weak, with a current ratio of 0.27 and negative operating cash flow of -$955,820, suggesting that it may struggle to meet short-term obligations without external financing. The company's free cash flow is also negative at -$2.93 million, further highlighting its cash flow challenges.
In terms of profitability, ABVC Biopharma Inc is currently unprofitable, with a net loss of -$2.83 million and an operating loss of -$2.84 million. The company's return on equity is -36.37%, and its return on assets is -19.6%, both significantly below the industry median for biotechnology firms. The company's gross profit margin is 76.86%, which is relatively high, but this is offset by substantial operating and net losses.
ABVC Biopharma Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's total revenue for the period is $1.21 million, and there is no information available on the geographic distribution of this revenue. The lack of segment and geographic diversification increases the company's exposure to market-specific risks.
The company's growth trajectory is uncertain, with no disclosed revenue growth or decline in the most recent financial period. The company's outlook for the current fiscal year is not provided, but the negative operating and net income suggest that the company is not currently generating sustainable growth. The company's ability to grow will depend on its success in developing and commercializing new therapies.
The company faces significant financial risks, including a high debt-to-equity ratio of 0.22 and a negative current ratio of 0.27. The company's liquidity risk is rated as medium, and its net cash position is negative after subtracting total debt. The company's dilution risk is rated as low, but the potential for dilution remains a concern given the company's need for additional capital.
Recent events related to ABVC Biopharma Inc include the filing of its latest financial statements, which disclose the company's current financial position and challenges. There are no recent transcripts or press releases that provide additional insight into the company's operations or strategic direction.
- ABVC Biopharma Inc is currently unprofitable with a net loss of -$2.83 million and an operating loss of -$2.84 million.
- The company's liquidity position is weak, with a current ratio of 0.27 and negative operating cash flow of -$955,820.
- The company's return on equity is -36.37%, and its return on assets is -19.6%, both significantly below the industry median for biotechnology firms.
- ABVC Biopharma Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification.
- The company's growth trajectory is uncertain, with no disclosed revenue growth or decline in the most recent financial period.
- The company faces significant financial risks, including a high debt-to-equity ratio of 0.22 and a negative current ratio of 0.27.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue $152.4k, −84,3% YoY; Operating income +55,5% YoY.
- ▍Revenue $152.4k, −84,3% YoY
- ▍Operating income +55,5% YoY
- ▍Net income +52,6% YoY
- ▍Free cash flow +51,7% YoY
- ▍Net margin -5109.3%
Revenue $969.8k, +172,6% YoY; Operating income −30,1% YoY.
- ▍Revenue $969.8k, +172,6% YoY
- ▍Operating income −30,1% YoY
- ▍Net income −27,9% YoY
- ▍Free cash flow −36,3% YoY
- ▍Net margin -1693.5%
Revenue $355.8k; Operating income -$11.7M.
- ▍Revenue $355.8k
- ▍Operating income -$11.7M
- ▍Net margin -3608.4%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- ABVC Biopharma Inc Market data — financials · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 7.1%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -65.1%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 179.3%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -52.0%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -61.3%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 174.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 13.9%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -32.5%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 7.1%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.70xDerived (calculated)
- Current ratio (FY 2025-12-31): 0.41xDerived (calculated)
- Return on assets (FY 2025-12-31): -37.5%Derived (calculated)
- Return on equity (FY 2025-12-31): -71.2%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 806.2%Derived (calculated)
- Pre-tax income (annual): USD -8.35MSEC XBRL filing
- Shares outstanding (annual): 25.05MSEC XBRL filing
- Total assets (annual): USD 21.06MSEC XBRL filing
- Current liabilities (annual): USD 6.16MSEC XBRL filing
- Current assets (annual): USD 2.5MSEC XBRL filing
- Net income (annual): USD -7.91MSEC XBRL filing
- Total operating expenses (annual): USD 7.15MSEC XBRL filing
- Total liabilities (annual): USD 7.76MSEC XBRL filing
- Operating cash flow (annual): USD -2.99MSEC XBRL filing
- Cash & equivalents (annual): USD 681.48KSEC XBRL filing